Tvardi
PublicTvardi is now publicly traded
The data on this page reflects Tvardi's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Equity
Dec 18, 2024
Total Funding Raised
$111.3M
Company Overview
Tvardi operates in Healthcare and is based in Sugar Land, Texas. It has raised $111.3M.
Tvardi Therapeutics is a biopharmaceutical company focused on developing small molecule inhibitors of STAT3 to provide innovative treatments for breast and lung cancer, as well as addressing various inflammatory and fibrotic diseases.
Sector
Healthcare
AI Layer
Non-AI
Tvardi Comparables
Compare Tvardi with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BirchBioMed Inc. | 75% | |
| AgomAb Therapeutics | 73% | |
| ImmunoMet Therapeutics | 72% |
For institutional investors. Book with your work email.
Tvardi Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Dec 18, 2024 | ||||
| Series B | Jun 23, 2021 | ||||
| Series A | Sep 20, 2018 |
For institutional investors. Book with your work email.
Tvardi Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ArrowMark Partners | Series B |
| National Foundation for Cancer Research | Series B |
| Palkon Capital Management | Series B |
| Slate Path Capital | Series B |
Tvardi Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.